Navigation Links
Tolerx Announces Amendment to Phase 3 DEFEND Protocol
Date:8/11/2009

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced changes to the protocol for its Phase 3 clinical trial DEFEND, which is testing the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

The DEFEND (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) protocol amendment includes two key changes to the study: expansion of the eligible patient age range from 18-35 years to 12-45 years, and the shortening of the infusion time for each administration of otelixizumab from 2 hours to 30 minutes. Both of these enhancements are supported by clinical data derived from Tolerx's ongoing Phase 2 study called TTEDD.

"From a clinical perspective, I believe this amendment significantly improves the protocol for the DEFEND trial," said Peter A. Gottlieb, MD, Associate Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado at Denver, and a principal investigator in the DEFEND study. "Most notably, through the expansion of the patient age range to include adolescents, Tolerx is widening the options available to physicians interested in providing new investigational treatment options to this important and growing adolescent patient population."

Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx, also commented on the news: "We are pleased with this amendment on multiple levels and are hopeful that both the expansion of the target population and the more convenient dosing regimen will further expand the enthusiasm for this trial in the diabetes community. Our commitment to type 1 diabetes patients is evidenced in our efforts to develop a short, conven
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Albany, New York (PRWEB) July 25, 2014 ... Transparency Market Research, "Biological Drugs Market - Global Industry ... 2020," the global biological drugs market is estimated at ... grow at a CAGR of 10.1% from 2014 to ... million in 2020. , The biological drugs market is ...
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... for the Study of ... DNA-Protein Interactions, ... launch of its Imprint(TM) Chromatin,Immunoprecipitation Kit for epigenetic research,( http://www.sigma.com/chip ... Immunoprecipitation, including columns and reagents,for DNA purification as well as ...
... April 16 Medarex, Inc.,(Nasdaq: MEDX ) ... that suggest a,potential association between higher doses of ... control and prolonged,progression-free survival in patients with relapsed ... 1/2 trial were presented at the,Annual Meeting of ...
... Masimo (Nasdaq:,MASI), the inventor of Pulse CO-Oximetry ... Atom Medical Corporation, a leading global manufacturer ... Rainbow SET Pulse,CO-Oximetry into its current and ... Masimo technology more than 10 years ago, ...
Cached Biology Technology:Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 2Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 3Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 2Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 3Atom Medical Adopts Masimo Rainbow SET Technology 2Atom Medical Adopts Masimo Rainbow SET Technology 3Atom Medical Adopts Masimo Rainbow SET Technology 4
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
(Date:7/25/2014)... from 25 countries and 35 states will attend ... Genetics Society of America (GSA) next week at ... will feature close to 500 presentations (including 70 ... gene expression and regulation, functional genomics, chemical biology ... a variety of diseases. , Of special ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... of an fMRI (functional magnetic resonance imaging) technique, ... Medicine have, for the first time, visualized the ... human brain. , Their work, performed at Penn's ... of psychological stress -- which will pave the ...
... some protection to the heart from injury even if ... attack, Jefferson Medical College researchers report. , Walter Koch, ... the Department of Medicine at Jefferson Medical College of ... that the drug Darbepoietin alpha would protect the ischemic ...
... two bacteria that cause significant damage to pig and ... are now analysing the results in an attempt to ... vaccines and diagnostic kits against the bacteria. , Mycoplasma ... pig-breeding industry US$200 million each year. Mycoplasma synoviae is ...
Cached Biology News:Research Permits First-Ever Visualization of Psychological Stress in the Human Brain 2
... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
... The first SpeedVac to have active, real-time ... SpeedVac System is the worlds first, fully ... can be stacked together to form an ... benchspace. It is also the first SpeedVac ...
... RC Standard Bio for vacuum concentrator/centrifugal ... molecular biology and biochemistry for rapid and ... systems can be expanded with pumps, different ... of rotors (eliminating sample loss by transfer), ...
... dedicated concentrator for efficient drying of small ... integrated system combines the SpeedVac™ Concentrator and ... automatic pump and rotor control, and dual ... heater time), makes the DNA120 indispensable in ...
Biology Products: